Outcomes after Stereotactic Body Radiotherapy for Treatment of Hepatocellular Carcinoma

Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma

Stereotactic body radiotherapy (SBRT) is a relatively new treatment for liver tumor. Outcomes of SBRT for liver tumors unsuitable for ablation or surgical resection were evaluated. A total of 79 patients treated with SBRT for primary hepatocellular carcinoma (HCC) between 2004 and 2012 in six Japanese institutions were studied retrospectively. Patients treated with SBRT preceded by trans-arteri...

Stereotactic ablative body radiotherapy for hepatocellular carcinoma or cholangiocarcinoma

Clinical outcomes of stereotactic body radiotherapy for spinal metastases from hepatocellular carcinoma

PURPOSE To investigate the outcomes of patients with spinal metastases from hepatocellular carcinoma (HCC), who were treated by stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS This retrospective study evaluated 23 patients who underwent SBRT from October 2008 to August 2012 for 36 spinal metastases from HCC. SBRT consisted of approximately 2 fractionation schedules, which were 18...

Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma

BACKGROUND Renal atrophy is observed in an irradiated kidney. The aim of this study was to determine dose-volume histogram parameters and other factors that predict renal atrophy after 10-fraction stereotactic body radiotherapy (SBRT) for primary renal cell carcinoma (RCC). METHODS A total of 14 patients (11 males, 3 females) who received SBRT for RCC at Tohoku University Hospital between Apr...

Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma

BACKGROUND To evaluate the efficacy and toxicity of stereotactic body radiotherapy (SBRT) in the treatment of advanced hepatocellular carcinoma (HCC). MATERIAL AND METHODS Patients with large HCCs (median diameter 7 cm, IQR 5-10 cm) with a Child-Turcotte-Pugh (CTP) score A (60%) or B (40%) and Barcelona-Clinic Liver Cancer (BCLC) classification stage B or C were treated with 3 to 12 fractions...